Results 191 to 200 of about 165,965 (304)

Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making. [PDF]

EClinicalMedicine
Moiz A, Peters TM, Tsoukas MA, Yu OHY, Filion KB, Eisenberg MJ.   +5 more
europepmc   +1 more source

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

British Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease. [PDF]

Int J Mol Sci
Gandhi A, Phyu EM, Koom-Dadzie K, Dickson KB, Halm J.   +4 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety. [PDF]

Diabetes Metab Res Rev
Lee N, Kim Y.
europepmc   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers. [PDF]

Ann Med
Chikatimalla R, Shah A, Shah T, Perry G, Banker H, Aggarwal K, Jain R.   +6 more
europepmc   +1 more source

Experimental peptides, GLP‐1s and polypharmacy: Future directions for image‐ and performance‐enhancing drug harm reduction

Addiction, EarlyView.
Luke A. Turnock, Lambros Lazuras
wiley   +1 more source

Amylin analogues as a novel perspective in anti‐obesity therapy

British Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source